Science news and discoveries from Mass General Brigham
Bench PressBench PressBench PressBench Press
  • Home
  • About Us
  • Research
    • Brain Research
    • Heart
    • Cancer
    • More…
Image of glial cells

Looking for Insights into Mucolipidosis IV

By mghresearch | Genetics & Genomics, Neurology, Rare Disease | 0 comment | 8 June, 2018 | 0
Headshot.jpg
Amanda Furness, PhD

Amanda Furness, PhD, is a postdoctoral research fellow in the Center for Genomic Medicine at Massachusetts General Hospital. Her poster, Therapeutic insight into Mucolipidosis IV via in vitro glia models, recently won an award at Mass General’s Research Fellow Poster Celebration.

We asked Dr. Furness about her research:

What problem(s) are you addressing with this research?

Our lab is studying Mucolipidosis IV (MLIV), a genetic neurologic disease that affects children.

Affected individuals have intellectual disability, limited or absent speech, difficulty chewing and swallowing, weak muscle tone that gradually turns into abnormal muscle stiffness, and problems controlling hand movements. Most are unable to walk independently.

Patients typically remain stable into their 20s and 30s when they start to develop corneal clouding, leading to blindness. Although MLIV is a pan-ethnic disease, the vast majority of MLIV patients are of Ashkenazi Jewish decent.

To date, there is neither a specific treatment for MLIV, nor a complete mechanistic model explaining its pathology.

Our goal is to investigate, understand, and control the pathways affected by the disease and ameliorate the resulting clinical manifestations of MLIV.

What methods did you use?

Previous members of the lab have developed and characterized the MLIV mouse model, which is an excellent model of the disease.

We have used this model to study various aspects of the disease ranging from cellular signatures to motor function.

Our prior research has shown that neuroinflammation caused by dysfunction of cells in the central nervous system — called glial cells — is an early and important sign of MLIV.

Thus, in our recently presented and published research, we developed in vitro models for two subtypes of glial cells, astrocytes and microglia, that model the dysfunction of these cells in individuals with MLIV.

The cultured cells from MLIV mice were investigated using an assay to monitor changes in proinflammatory molecule production. 

The cells were also imaged using a microscope to look at structure, markers of inflammation, and the contents of lysosomes — enzyme-containing organelles that break down a variety of biomolecules.

What results did you find and how do your results expand our understanding of this topic?

The in vitro models we developed provide both a phenotypical representation of the disease, as well as mechanistic insight into the glial function in MLIV.

In attempts to find strategies to slow the progression of MLIV, we also tested fingolimod, an FDA approved drug for multiple sclerosis, on our MLIV cells.

Our data show that this drug reduces pro-inflammatory signaling in cultured astrocytes from MLIV mice.

Furthermore, fingolimod was also able to correct lysosomal impairment, which is a primary consequence of the disease.

What are the implications for clinical care?

Because we saw cell function recovery and proinflammatory reduction in our cell models, we can now move to a pre-clinical trial where we will determine if fingolimod can recover motor and muscle function in our MLIV mice.

Success in this trial will hopefully pave the way for a clinical trial in MLIV patients.  We are currently using the glia models to screen additional drugs for other pre-clinical trials.

Our ultimate goal is to discover several compounds which could be given to MLIV patients to attack the disease and recover function from several angles.

Check out a recently published article highlighting this research!

About the Mass General Research Institute
Research at Massachusetts General Hospital is interwoven through more than 30 different departments, centers and institutes. Our research includes fundamental, lab-based science; clinical trials to test new drugs, devices and diagnostic tools; and community and population-based research to improve health outcomes across populations and eliminate disparities in care.
Support our Research

No tags.

Related Post

  • To Mars and Beyond: Exploring Innovative Solutions to the Challenges of Space Travel

    By mghresearch | 1 comment

    If you could only bring two shoeboxes worth of medical supplies—from first aid kits to surgical tools— with you on a three-year space mission, what would you bring?

  • Antibiotic pills

    Are You Actually Allergic to Penicillin? Researchers Find New Methods to Confirm Antibiotic Allergies

    By mghresearch | 0 comment

    Mass General researchers are working to increase the safe use of penicillins in patients who have a recorded penicillin allergy but are not actually allergic.

  • Re-Thinking Mental Health Treatment: World Health Day 2017

    By mghresearch | 0 comment

    Did you know that more than 300 million people worldwide live with depression? That number has increased 18% between 2005 and 2015, according to the World Health Organization (WHO). With such staggering numbers, it’s no surprise that WHO has chosen depression as its theme for this year’s World Health Day, which is celebrated today, April 7th.

  • New Study Finds Low-Dose Aspirin May Lower Risk of Cancer Death

    By mghresearch | 1 comment

    A new study from Massachusetts General Hospital reports that long-term regular aspirin was associated with a lower risk of dying from various types of cancers.

  • Mass General Stands Up for Science

    By mghresearch | 0 comment

    The Boston March for Science will celebrate the discovery, understanding and sharing of scientific knowledge. Several groups from Massachusetts General Hospital are working together to organize and ensure a strong presence to reaffirm the message about the essential role that science – biomedical research, in particular – plays in improving life and health.

  • Adhering to Treatment During Adolescence Keeps HIV-Positive Youth on a Healthier Track

    By mghresearch | 0 comment

    Individuals born with HIV are more likely to have difficulty managing their treatment as teens and young adults than they did as children.

  • Celebrating the Role of Women in Science and Much More

    By mghresearch | 2 comments

    Interested in the newest research studies and hot topics? Check out the latest issues of “From the Lab Bench”, a monthly newsletter from the Office of the Scientific Director at the Mass General Research Institute, and “Research Roundup”, our monthly recap of the latest biomedical research news.

  • Research Rumble Recap and the Art of Effective Science Communication

    By mghresearch | 1 comment

    Last night five researchers from Massachusetts General Hospital and Brigham and Women’s Hospital showed off their science communication skills in a Research Rumble at the Cambridge Public Library as part of Cambridge Science Festival. Co-DirectorRead more

Leave a Comment

Cancel reply

Your email address will not be published. Required fields are marked *

  • About
  • About Us
  • Brain Research
  • Cancer
  • Communicating Science
  • Contenido en español
  • COVID-19
  • Events
  • Heart
  • History
  • Home (OLD)
    • Disclaimer
    • Home
  • Just kidding!
  • MGH Chief Academic Officer Job Description
  • MGRI Image Awards
  • MGRI Image Awards
  • MGRI Science Communications Intern
  • Research
  • Research News Funding Opportunities
  • Research News: Announcements & Events
  • Science Slam Tips and Tricks
  • Subscribe
Bench Press